(Q39382203)

11 September 2017

title

The recombinant globular head domain of the measles virus hemagglutinin protein as a subunit vaccine against measles (English)

1 reference

11 September 2017

1 reference

4

George K Mutwiri

1 reference

11 September 2017

Liubov M Lobanova

1

1 reference

11 September 2017

Nelson F Eng

2

1 reference

11 September 2017

Malathy Satkunarajah

3

1 reference

11 September 2017

James M Rini

5

1 reference

11 September 2017

Alexander N Zakhartchouk

6

1 reference

11 September 2017

language of work or name

English

0 references

publication date

8 March 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

30

1 reference

11 September 2017

issue

20

1 reference

11 September 2017

page(s)

3061-3067

1 reference

Global measles elimination

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Measles vaccination: new strategies and formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Use of cotton rats for preclinical evaluation of measles vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Depletion of measles virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Monoclonal Antibodies Against Measles Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Crystal structure of measles virus hemagglutinin provides insight into effective vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Structure of the measles virus hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Role of N-linked oligosaccharide chains in the processing and antigenicity of measles virus haemagglutinin protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

X-ray crystal structure determination of mammalian glycosyltransferases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Mucosal adenovirus-vectored vaccine for measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Mechanism of action of clinically approved adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Large-scale preparation of biologically active measles virus haemagglutinin expressed by attenuated vaccinia virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

The development of a plant-based vaccine for measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Serologic response of children to in-activated measles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Reactions to Live-Measles-Virus Vaccine in Children Previously Inoculated with Killed-Virus Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Specific CD8(+) T-lymphocytes control dissemination of measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the beta-galactosidase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

inferred from DOI database lookup

7 January 2021

based on heuristic

High-level eucaryotic in vivo expression of biologically active measles virus hemagglutinin by using an adenovirus type 5 helper-free vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.067

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.02.067

1 reference

11 September 2017

1 reference